Navigation Links
Adaptive TCR Launches the immunoSEQ™ Product Line - Visualizing the Immune System With Next-Generation Sequencing.
Date:10/20/2010

SEATTLE, Oct. 20 /PRNewswire/ -- Adaptive TCR Technologies, a biotech firm based in Seattle, WA, announced today the release of its immunoSEQ™ profiling service and immunoSEQ Analyzer™ bioinformatics software platform.  Together, these tools provide researchers and clinicians the ability to profile and monitor the adaptive immune system at a level of detail that has never before been possible.

"ImmunoSEQ represents one of the first specific applications of next-generation sequencing technology," offers Chad Robins, CEO and Founder of Adaptive TCR. "We have delivered the Hubble Telescope as compared to a pair of binoculars to look at the adaptive immune system."

ImmunoSEQ assays use proprietary chemistry to amplify the rearranged CDR3 regions of T-cell receptor (TCR) genes responsible for most TCR diversity.  Each immunoSEQ assay can generate millions of cell-specific sequences, allowing a remarkably deep characterization of the T-cell repertoire in any sample.  To analyze this large amount of data, Adaptive TCR provides access to the immunoSEQ Analyzer, a bioinformatics software platform comprising a suite of tools designed specifically to handle immunoSEQ data.  

"Using DNA sequencing to look at cells of the immune system is particularly powerful," said Dr. Harlan Robins, a computational biologist at the Fred Hutchinson Cancer Research Center and co- founder of Adaptive TCR. "By bringing together unique amplification chemistries, massively parallel sequencing and powerful, user-friendly software, we are providing access to the adaptive immune system in unbelievable detail."  

In addition to providing information on the basic functioning of the immune system, immunoSEQ data can contribute to the understanding and development of many important medical conditions and applications, including cancer immunotherapy, autoimmune disorders, vaccine development, and infectious disease.  "We know that T cells are involved in autoimmune diseases like Type 1 Diabetes, Multiple Sclerosis, Rheumatoid Arthritis and others," noted Dr. Christopher Carlson, an investigator at the Fred Hutchinson Cancer Research Center and a co-founder of Adaptive TCR.  "Now we can examine what's going on in incredible detail, and hopefully we will find tests based on T-cell repertoires that give physicians prognostic information and treatment guidance."

ImmunoSEQ assays and the immunoSEQ Analyzer are easily available to any researcher.  The researcher or clinician need only provide a DNA sample; the company does all the laboratory work, and uploads the resulting sequence data to a secure web site that is available to the researcher at all times. "The true value to our clients lies in the combination of the assay with a user-friendly, powerful software suite for data analysis, visualization, and interpretation," adds CEO Robins.  

Robins believes that the industry is at the very beginning, "as our technology becomes increasingly powerful, we look forward to witnessing clients using immunoSEQ to answer fundamental questions in the field of adaptive immunity, leading to a better quality of life for people afflicted with dysfunctional immune systems."

About Adaptive TCR Corporation

Adaptive TCR Corporation, headquartered in Seattle, WA, develops, commercializes and supports online solutions for large scale immune system profiling. Adaptive TCR's proprietary technologies were developed at the Fred Hutchinson Cancer Research Center by co-founders Harlan Robins, PhD and Chris Carlson, PhD. The technologies include a DNA amplification chemistry that can generate many millions of T cell receptor sequences from a single DNA sample, and a bioinformatics software suite designed specifically to manage the large amounts of data resulting from a typical assay. These technologies are marketed for life science research applications under the brand name immunoSEQ™ and immunoSEQ Analyzer™. The company began commercial operations in 2009 under the leadership of Chad Robins, CEO.


'/>"/>
SOURCE Adaptive TCR Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Adaptive Trial Paper Explores Benefits of Adaptive Trials for Phase I, Phase II Studies
2. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
3. Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the Worlds First Adaptive 128-slice CT Scanner
4. Prometheus Research Launches Solutions Group to Springboard HTSQL-based Solutions for Customers
5. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
6. CoreLab Partners Launches New DXA Imaging Service Offerings
7. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
8. InSightec Launches ExAblate(R) One and ExAblate(R) OR Systems at CIRSE 2010
9. Michael J. Fox Foundation Launches Parkinsons Progression Markers Initiative (PPMI)
10. HelixLife Launches Custom Health Supplements, Anti-Aging and Acne Skin Serums
11. Norgen Biotek Corp. Launches a Novel kit to Collect, Concentrate, Preserve and Isolate DNA, RNA, microRNA and proteins from Urine Specimens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/11/2017)... Tampa Bay, Florida (PRWEB) , ... October 11, ... ... Food and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its ... antibody (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
Breaking Biology News(10 mins):